Study of Epratuzumab in Systemic Lupus Erythematosus

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: Epratuzumab

Criteria

Inclusion Criteria:

• Must have completed SL0003 Alleviate A through 48 weeks

Exclusion Criteria:

• Development of toxicity to Epratuzumab

• Significant protocol deviations from SL0003 Study.